Pembrolizumab monotherapy for patients with PD-L1 ≥ 1% is the only chemotherapy-spared therapy approved by US FDA for the first-line treatment of advanced NSCLC patients based on the trial of KEYNOTE-042 (10). Here, CD274 is linked to non-small cell lung carcinoma.